Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer

Abstract

Linac-based stereotactic radiotherapy has little effect on the majority of advanced neoplasms. Therefore, the novel radiosensitizer Kochi oxydol-radiation therapy for unresectable carcinomas (KORTUC) II, which contains hydrogen peroxide and sodium hyaluronate, was developed. The effectiveness of KORTUC II for the treatment of chemotherapy-resistant supraclavicular lymph node metastases, recurrent breast cancer and stage IV primary breast cancer has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II for patients with stage I primary breast cancer. A total of 15 patients (age range, 40–76 years) were enrolled. The injection of 3 ml of KORTUC II agent was initiated from the sixth radiotherapy fraction and was performed twice a week, under ultrasonographic guidance. The therapeutic effects were evaluated by PET-CT and/or MRI examinations prior to and following KORTUC II treatment. All patients exhibited complete responses and the overall survival rate was 100% after a follow-up period of five years. The mean duration of follow-up at the end of March 2015 was 53 months. Based on these results, KORTUC II treatment exhibited marked therapeutic effects with satisfactory treatment outcomes and an acceptable extent of adverse events.

Evaluation of the radiosensitizing potency of bromelain for radiation therapy of 4T1 breast cancer cells

“…[126] Futhermore, many researchers worked on many cells, including LY2603618, MK87776, and AZD1775 on human papillomavirus(+) human head-and-neck squamous cell carcinoma (HNSCC) cells; UD-SCC-2, UM-SCC-47, and UPCI-SCC-154, EhB4 on HNSCC cells; Cal27, MSK-921, and Fadu, Human polo-like kinase 1 (PLK1) on human esophageal squamous cell carcinoma cells; KYSE 70, and KYSE 150, ganetespib on human Hepatocellular carcinoma cells; Hep3b, HepG2 and HUH, AZD6738 and ATM inhibitor KU-55933 on different cell lines; CAL27, FaDu, A549, PJ34, PJ41, T24, A2780, RT4, NCI-H1838, NCI-H1373, and DU-4475, MZ-6 and MZ-14 on human hepatocellular liver carcinoma cell line HepG2. [382728293031] Outcomes of this study are in good agreement with their results.…”

“…Clinically conventional treatment has been adopted for BC treatment mainly including chemotherapy, surgery, radiotherapy (RT), and some combined treatment strategies. [ 1 2 3 4 5 ] Chemotherapy is used for systemic control, whereas surgery and RT are used to the management of cancer. RT is commonly recommended as primary or adjuvant treatment modality for BC with the benefit rate as high as 80%–90%.…”

“…In addition, the majority of cancer types contain a high degree of heterogeneity in microenvironment, phenotype, genotype, many hypoxic cells, and huge amount of enzymes should be protected cells to RT and variability in radiation sensitivity. [ 1 2 3 4 ] To address these challenges, tumor-selective radiosensitizers which can increase the selectivity of ionizing radiation (IR) to cancer cell without hampering the activities of healthy cells are extremely desired and have been widely investigated. The use of radiosensitizers combined with low-linear energy transfer radiations can increase normal tissue radioresistance, therapeutic efficacy by allowing to decrease the essential treatment irradiation dose, and resulting in minimizing the risk of recurrence.…”

Imaging of Hydroxyl-Radical Generation Using Dynamic Nuclear Polarization-Magnetic Resonance Imaging and a Spin-Trapping Agent

“…The novel KORTUC II radiosensitizer, which contains H 2 O 2 and sodium hyaluronate, was developed to address this shortcoming. The effectiveness of KORTUC II for the treatment of chemotherapy-resistant supraclavicular lymph node metastases, recurrent breast cancer, and stage-IV primary breast cancer has previously been demonstrated. − Because KORTUC II administers radiation therapy after injecting a drug containing H 2 O 2 into the tumor tissue, it is assumed that there is a high concentration of H 2 O 2 in the tumor region. Therefore, our methodology might be used to understand the localization of radicals within the treatment site by administration of DMPO.…”

New enzyme‑targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer

“…This suggests it is a safe sensitizer if proper dosage is used and attention is paid to avoid procedural problems such as incorrect administration into blood vessels (5). The severity of acute-phase adverse events, such as radio-dermatitis, has been reported to be comparable with that following adjuvant radiation for regular breast-conserving therapy (13)(14)(15). Also, no particular delay in acute-phase injuries has been observed.…”